Terms: = Ovarian cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Treatment
25 results:
1. Review on Sertoli-Leydig Cell Tumours of the Ovary.
Muscat C; Calleja-Agius J
Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
[TBL] [Abstract] [Full Text] [Related]
2. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract] [Full Text] [Related]
3. Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.
Johnson J; Kim SY; Sam PK; Asokan R; Cari EL; Bales ES; Luu TH; Perez L; Kallen AN; Nel-Themaat L; Polotsky AJ; Post MD; Orlicky DJ; Jordan KR; Bitler BG
Am J Reprod Immunol; 2023 Mar; 89(3):e13649. PubMed ID: 36394352
[TBL] [Abstract] [Full Text] [Related]
4. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of ovarian cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract] [Full Text] [Related]
5. Progress in the management of ovarian granulosa cell tumor: A review.
Li J; Chu R; Chen Z; Meng J; Yao S; Song K; Kong B
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1771-1778. PubMed ID: 34027996
[TBL] [Abstract] [Full Text] [Related]
6. DSCMF: prediction of LncRNA-disease associations based on dual sparse collaborative matrix factorization.
Liu JX; Gao MM; Cui Z; Gao YL; Li F
BMC Bioinformatics; 2021 May; 22(Suppl 3):241. PubMed ID: 33980147
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract] [Full Text] [Related]
8. ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
Pierini S; Tanyi JL; Simpkins F; George E; Uribe-Herranz M; Drapkin R; Burger R; Morgan MA; Facciabene A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814714
[TBL] [Abstract] [Full Text] [Related]
9. The molecular mechanism of ovarian granulosa cell tumors.
Li J; Bao R; Peng S; Zhang C
J Ovarian Res; 2018 Feb; 11(1):13. PubMed ID: 29409506
[TBL] [Abstract] [Full Text] [Related]
10. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2017 Sep; 18(9):705-714. PubMed ID: 28812434
[TBL] [Abstract] [Full Text] [Related]
11. Viral-induced Modulation of Multiple Checkpoint Proteins in cancers.
Nuovo GJ; Folcik VA; Magro C
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):407-414. PubMed ID: 28697066
[TBL] [Abstract] [Full Text] [Related]
12. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Weiss GJ; Waypa J; Blaydorn L; Coats J; McGahey K; Sangal A; Niu J; Lynch CA; Farley JH; Khemka V
Br J Cancer; 2017 Jun; 117(1):33-40. PubMed ID: 28588322
[TBL] [Abstract] [Full Text] [Related]
13. Immune Checkpoint Inhibitors: A New Opportunity in the treatment of ovarian cancer?
Mittica G; Genta S; Aglietta M; Valabrega G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27447625
[TBL] [Abstract] [Full Text] [Related]
14. Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.
Leung DTH; Fuller PJ; Chu S
Int J Biochem Cell Biol; 2016 Mar; 72():51-54. PubMed ID: 26791928
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial.
Nakamura K; Sawada K; Sugiyama M; Mabuchi S; Hisamatsu T; Nishio Y; Ito K; Kimura T; Kamiura S; Morishige K
Int J Gynecol Cancer; 2015 Feb; 25(2):288-95. PubMed ID: 25569817
[TBL] [Abstract] [Full Text] [Related]
16. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Gatalica Z; Snyder C; Maney T; Ghazalpour A; Holterman DA; Xiao N; Overberg P; Rose I; Basu GD; Vranic S; Lynch HT; Von Hoff DD; Hamid O
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2965-70. PubMed ID: 25392179
[TBL] [Abstract] [Full Text] [Related]
17. [Anti-PD-1 antibody: basics and clinical application].
Tanaka Y; Okamura H
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
[TBL] [Abstract] [Full Text] [Related]
18. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.
Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R
PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212
[TBL] [Abstract] [Full Text] [Related]
19. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
[TBL] [Abstract] [Full Text] [Related]
20. Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity.
Linares F; Galindo MA; Galli S; Romero MA; Navarro JA; Barea E
Inorg Chem; 2009 Aug; 48(15):7413-20. PubMed ID: 19586019
[TBL] [Abstract] [Full Text] [Related]
[Next]
